| Species | Gene ID | Accession | EC | Source | Length | MW | Tag |
| 2019-nCoV | 43740568 | QHD43416 | - | HEK293 | 223 (w/o tag) | ~26kDa | C-His |
| 蛋白信息(About this protein) | |
| 名称(Name) | 2019-nCoV Spike Protein RBD (Delta, L452R, T478K, 319-541, 印度突变株)；319-541aa |
| 别名(Synonyms) | RBD domain of 2019-nCoV Spike Protein, 2019-nCoV Spike Protein S1 RBD, Spike Protein S1 Subunit RBD of 2019-nCoV, 2019-nCov RBD Protein, 2019-nCoV Spike RBD Protein, L452R and T478K Mutation, First identified in India (B.1.617.2). |
| 产品简介(Background) | SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. Spike Protein, the main surface antigen of the coronavirus, is a ∼180kD glycoprotein that crucial for viral fusion and entry into the host cells. It is a homotrimeric, consisting of two subunits, S1 and S2. In SARS-CoV-2, proteolytic cleavage of spike protein into S1 and S2 subunits is required for its activation. The first step of coronavirus infection of virus is the interaction of the spike protein to certain receptors on host cells. The S1 subunit is focused on attachment of the protein to the receptor while the S2 subunit is involved with membrane fusion. The receptor binding domain (RBD) locates in the C-terminal region of S1, and it binds to Angiotensin-Convertin434g Enzyme 2 (ACE2) of host cells with high affinity and fast binding kinetic. Blocking the interaction between ACE2 and RBD inhibits the viral infection. RBD-specific antibodies have been shown to inhibit the attachment of RBD to ACE2-expressing cells, suggesting RBD as a potential target for vaccinations or therapy of SARS-CoV-2 infection. The attributes of Delta variants: Increased transmissibility; Potential reduction in neutralization by some EUA monoclonal antibody treatments; Potential reduction in neutralization by post-vaccination sera. |
| 产品用途(Applications) | 用于新型冠状病毒抑制剂的筛选、抗体制备、ELISA的标准蛋白或结构研究 |
| 外观(Physical appearance) | 液体 |
| 活性(Biological activity) | - |
| 活力单位(Unit definition) | - |
| 浓度(Concentration) | ≥0.1mg/ml |
| 纯度(Purity) | ≥ 95% by SDS-PAGE. |
| 配方(Formulation) | PBS, pH7.4 |
| 使用方法(Recommended usage) | - |
| 氨基酸序列(Amino acid sequence) | RVQPTESIVR FPNITNLCPF GEVFNATRFA SVYAWNRKRI SNCVADYSVL YNSASFSTFK CYGVSPTKLN DLCFTNVYAD SFVIRGDEVR QIAPGQTGKI ADYNYKLPDD FTGCVIAWNS NNLDSKVGGN YRYLYRLFRK SNLKPFERDI STEIYQAGSK PCNGVEGFNC YFPLQSYGFQ PTNGVGYQPY RVVVLSFELL HAPATVCGPK KSTNLVKNKC VNFhhhhhh 备注：本氨基酸序列仅供参考，含C-His序列，实际氨基酸长度或序列可能有一定变化。 |
| 产品编号 | 产品名称 | 包装 |
| P2341-200μg | 2019-nCoV Spike Protein RBD (Delta, L452R, T478K, 319-541) | 200μg |
| P2341-1mg | 2019-nCoV Spike Protein RBD (Delta, L452R, T478K, 319-541) | 200μg×5 |
| － | 说明书 | 1份 |
-20℃保存，一年有效。-80℃保存，两年有效。
注意事项：分装后-20℃或更低温度冻存，以避免反复冻融。
收到产品后请立即按照说明书推荐的条件保存。在打开管盖前，请适当离心，使附着在管盖或管壁上的蛋白聚集于管底。
本产品仅限于专业人员的科学研究用，不得用于临床诊断或治疗，不得用于食品或药品，不得存放于普通住宅内。
为了您的安全和健康，请穿实验服并戴一次性手套操作。
| 产品编号 | 产品名称 | 包装 |
| P2331-200μg | 2019-nCoV Spike Protein RBD (新冠病毒S蛋白RBD区域) | 200μg |
| P2331-1mg | 2019-nCoV Spike Protein RBD (新冠病毒S蛋白RBD区域) | 1mg |
| P2333-200μg | 2019-nCoV Spike Protein RBD (E484K) | 200μg |
| P2333-1mg | 2019-nCoV Spike Protein RBD (E484K) | 1mg |
| P2335-200μg | 2019-nCoV Spike Protein RBD (N501Y) | 200μg |
| P2335-1mg | 2019-nCoV Spike Protein RBD (N501Y) | 1mg |
| P2337-200μg | 2019-nCoV Spike Protein RBD (K417N, E484K, N501Y) | 200μg |
| P2337-1mg | 2019-nCoV Spike Protein RBD (K417N, E484K, N501Y) | 1mg |
| P2339-200μg | 2019-nCoV Spike Protein RBD (Delta, L452R, T478K, 319-535) | 200μg |
| P2339-1mg | 2019-nCoV Spike Protein RBD (Delta, L452R, T478K, 319-535) | 1mg |
| P2341-200μg | 2019-nCoV Spike Protein RBD (Delta, L452R, T478K, 319-541) | 200μg |
| P2341-1mg | 2019-nCoV Spike Protein RBD (Delta, L452R, T478K, 319-541) | 1mg |
